Lilly will increase Indiana funding to $9 billion for weight reduction medicine
Eli Lilly and Co., is greater than doubling its funding in an Indiana manufacturing web site to extend manufacturing of components in its blockbuster weight reduction and diabetes medicine.
The growth to provide the components in Zepbound and Mounjaro will enhance the price of the venture from $3.7 billion to $9 billion.
“At the moment’s announcement tops the most important manufacturing funding in our firm’s historical past and,we imagine, represents the one largest funding in artificial drugs API manufacturing in U.S.historical past,” mentioned David A. Ricks, Lilly’s chair and CEO, in a ready assertion.
A KFF evaluation discovered Medicare spending on three medicine − Novo Nordisk’s Ozempic and Rybelsus and Eli Lilly’s Mounjaro − surged from $57 million in 2018 to $5.7 billion in 2022.
This story will likely be up to date.
Binghui Huang may be reached at Bhuang@gannett.com or 317-385-1595
